How best to protect your patients at risk for fracture? Test your knowledge with this 10-question quiz.
News
Be vigilant for the development of type 2 diabetes in patients with systemic lupus erythematosus.
Complete remission remains an elusive goal.
A green light for dosing to achieve the target urate level.
There were decreased reports of pain when the patients believed treatment would work, and different brain regions were activated during real versus sham treatment.
Results of a recent meta-analysis fly in the face of established guidelines.
New data highlight the role of the C5a-C5aR axis in the onset of inflammation.
Moderate to high disease activity may persist.
In which patients with inflammatory back pain, does it make sense to repeat magnetic resonance scanning of the spine?
The implications for disease activity and quality of life when these disorders coexist.
Your encouragement has a measurable impact on your patients’ physical activity.
Drink up-but in moderation.
Do you have a case that can teach and inspire other clinicians?
The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.
Recently published EULAR/ACR classification criteria generally perform better than previous criteria.
A reliable biomarker linked to outcomes represents another step toward the goal of individualized treatment.
An accurate, inexpensive alternative for examining smaller joints is at hand.
No differences were observed in patellofemoral joint morphology between asymptomatic patients and those with pain.
High-risk patients, such as older women, are most likely to benefit.
Take reports of joint crepitus seriously, especially in older patients.
The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.
While vitamin D may help ward off the onset of RA, it is less effective once the disease is established.
Early intervention may prevent or delay the development of RA.
Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.
The monotherapy resulted in LDA by week 14 in both the 15 mg (45%) and 30 mg (53%) groups.
A commonly held belief has been debunked.
Rheumatology Network Writing Contest Official Rules
The aim of this study: to determine which patients need biologic therapy after starting methotrexate.
Among the culprits: sunlight, cigarettes, and oral contraceptives.
What underlies the disparity in life expectancy between men and women with SLE?
Advertisement
Advertisement